Sign In

Login

Password

Forgot Password ? Sign Up

Saccharomyces boulardii (Turkish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Saccharomyces boulardii" in Turkish language version.

refsWebsite
Global rank Turkish rank
21doi.org
2nd place
4th place
20nih.gov
4th place
11th place
6web.archive.org
1st place
1st place
3ftb.com.hr
low place
low place
2harvard.edu
18th place
47th place
2europa.eu
68th place
79th place
1archive.org
6th place
6th place
1scitechdaily.com
low place
low place

archive.org

doi.org

  • Malgoire JY, Bertout S, Renaud F, Bastide JM, Mallié M (March 2005). "Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism". Journal of Clinical Microbiology. 43 (3). ss. 1133-1137. doi:10.1128/JCM.43.3.1133-1137.2005. PMC 1081240 $2. PMID 15750073. 
  • Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC 5428479 $2. PMID 28336969.  [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
  • Rajkowska K, Kunicka-Styczyńska A (January 2009). "Phenotypic and genotypic characterization of probiotic yeasts". Biotechnology & Biotechnological Equipment. 23 (supplement 1). ss. 662-5. doi:10.1080/13102818.2009.10818511. 
  • McFarland LV, Bernasconi P (1993). "Saccharomyces boulardii: a review of an innovative biotherapeutic agent". Microb Ecol Health Dis. 6 (4). ss. 157-71. doi:10.3109/08910609309141323. 
  • Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC 4959471 $2. PMID 26850302. 
  • "Scientific Opinion on the substantiation of health claims related to Saccharomyces cerevisiae var. boulardii CNCM I-1079 and defence against pathogenic gastro-intestinal microorganisms (ID 913, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006". EFSA Journal (İngilizce). 10 (6). June 2012. doi:10.2903/j.efsa.2012.2717. 
  • Kotowska M, Albrecht P, Szajewska H (March 2005). "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial". Alimentary Pharmacology & Therapeutics. 21 (5). ss. 583-590. doi:10.1111/j.1365-2036.2005.02356.x. PMID 15740542. 
  • Doron SI, Hibberd PL, Gorbach SL (July 2008). "Probiotics for prevention of antibiotic-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S58-S63. doi:10.1097/MCG.0b013e3181618ab7. PMID 18542041. 
  • Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S64-S70. doi:10.1097/MCG.0b013e3181646d09. PMID 18545161. 
  • Szajewska H, Kołodziej M (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7). ss. 793-801. doi:10.1111/apt.13344. PMID 26216624. 
  • Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC (April 2019). "Probiotics for the prevention of pediatric antibiotic-associated diarrhea". The Cochrane Database of Systematic Reviews. 4 (4). ss. CD004827. doi:10.1002/14651858.CD004827.pub5. PMC 6490796 $2. PMID 31039287. 
  • Tung JM, Dolovich LR, Lee CH (December 2009). "Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review". Canadian Journal of Gastroenterology. 23 (12). ss. 817-821. doi:10.1155/2009/915847. PMC 2805518 $2. PMID 20011734. 
  • Szajewska H, Horvath A, Kołodziej M (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12). ss. 1237-1245. doi:10.1111/apt.13214. PMID 25898944. 
  • Roberts T, Stark D, Harkness J, Ellis J (28 Mayıs 2014). "Update on the pathogenic potential and treatment options for Blastocystis sp". Gut Pathogens. Cilt 6. s. 17. doi:10.1186/1757-4749-6-17. PMC 4039988 $2. PMID 24883113. 
  • Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y (March 2011). "Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection". Parasitology Research. 108 (3). ss. 541-545. doi:10.1007/s00436-010-2095-4. PMID 20922415. 
  • Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, ve diğerleri. (April 2014). "Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics". Journal of Pediatric Gastroenterology and Nutrition. 58 (4). ss. 531-539. doi:10.1097/MPG.0000000000000320. PMID 24614141. 
  • Capece A, Romaniello R, Pietrafesa A, Siesto G, Pietrafesa R, Zambuto M, Romano P (November 2018). "Use of Saccharomyces cerevisiae var. boulardii in co-fermentations with S. cerevisiae for the production of craft beers with potential healthy value-added". International Journal of Food Microbiology. Cilt 284. ss. 22-30. doi:10.1016/j.ijfoodmicro.2018.06.028. PMID 29990636. 
  • Stenman LK, Burcelin R, Lahtinen S (February 2016). "Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics". Beneficial Microbes. 7 (1). ss. 11-22. doi:10.3920/BM2015.0069. PMID 26565087. 
  • Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, ve diğerleri. (2014). "Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum". International Journal of Immunopathology and Pharmacology. 27 (1). ss. 143-146. doi:10.1177/039463201402700120. PMID 24674691. 
  • Kelesidis T, Pothoulakis C (March 2012). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2). ss. 111-125. doi:10.1177/1756283X11428502. PMC 3296087 $2. PMID 22423260. 
  • Sulik-Tyszka B, Snarski E, Niedźwiedzka M, Augustyniak M, Myhre TN, Kacprzyk A, ve diğerleri. (June 2018). "Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients". Probiotics and Antimicrobial Proteins. 10 (2). ss. 350-355. doi:10.1007/s12602-017-9332-4. PMC 5973998 $2. PMID 28948565. 

europa.eu

ema.europa.eu

ftb.com.hr

harvard.edu

adsabs.harvard.edu

  • Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC 5428479 $2. PMID 28336969.  [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
  • Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC 4959471 $2. PMID 26850302. 

nih.gov

ncbi.nlm.nih.gov

  • Malgoire JY, Bertout S, Renaud F, Bastide JM, Mallié M (March 2005). "Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism". Journal of Clinical Microbiology. 43 (3). ss. 1133-1137. doi:10.1128/JCM.43.3.1133-1137.2005. PMC 1081240 $2. PMID 15750073. 
  • Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC 5428479 $2. PMID 28336969.  [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
  • Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC 4959471 $2. PMID 26850302. 
  • McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, ve diğerleri. (March 1995). "Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo". The American Journal of Gastroenterology. 90 (3). ss. 439-448. PMID 7872284. 
  • Kotowska M, Albrecht P, Szajewska H (March 2005). "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial". Alimentary Pharmacology & Therapeutics. 21 (5). ss. 583-590. doi:10.1111/j.1365-2036.2005.02356.x. PMID 15740542. 
  • Doron SI, Hibberd PL, Gorbach SL (July 2008). "Probiotics for prevention of antibiotic-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S58-S63. doi:10.1097/MCG.0b013e3181618ab7. PMID 18542041. 
  • Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S64-S70. doi:10.1097/MCG.0b013e3181646d09. PMID 18545161. 
  • Szajewska H, Kołodziej M (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7). ss. 793-801. doi:10.1111/apt.13344. PMID 26216624. 
  • Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC (April 2019). "Probiotics for the prevention of pediatric antibiotic-associated diarrhea". The Cochrane Database of Systematic Reviews. 4 (4). ss. CD004827. doi:10.1002/14651858.CD004827.pub5. PMC 6490796 $2. PMID 31039287. 
  • Tung JM, Dolovich LR, Lee CH (December 2009). "Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review". Canadian Journal of Gastroenterology. 23 (12). ss. 817-821. doi:10.1155/2009/915847. PMC 2805518 $2. PMID 20011734. 
  • Szajewska H, Horvath A, Kołodziej M (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12). ss. 1237-1245. doi:10.1111/apt.13214. PMID 25898944. 
  • Roberts T, Stark D, Harkness J, Ellis J (28 Mayıs 2014). "Update on the pathogenic potential and treatment options for Blastocystis sp". Gut Pathogens. Cilt 6. s. 17. doi:10.1186/1757-4749-6-17. PMC 4039988 $2. PMID 24883113. 
  • Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y (March 2011). "Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection". Parasitology Research. 108 (3). ss. 541-545. doi:10.1007/s00436-010-2095-4. PMID 20922415. 
  • Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, ve diğerleri. (April 2014). "Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics". Journal of Pediatric Gastroenterology and Nutrition. 58 (4). ss. 531-539. doi:10.1097/MPG.0000000000000320. PMID 24614141. 
  • Capece A, Romaniello R, Pietrafesa A, Siesto G, Pietrafesa R, Zambuto M, Romano P (November 2018). "Use of Saccharomyces cerevisiae var. boulardii in co-fermentations with S. cerevisiae for the production of craft beers with potential healthy value-added". International Journal of Food Microbiology. Cilt 284. ss. 22-30. doi:10.1016/j.ijfoodmicro.2018.06.028. PMID 29990636. 
  • Stenman LK, Burcelin R, Lahtinen S (February 2016). "Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics". Beneficial Microbes. 7 (1). ss. 11-22. doi:10.3920/BM2015.0069. PMID 26565087. 
  • Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, ve diğerleri. (2014). "Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum". International Journal of Immunopathology and Pharmacology. 27 (1). ss. 143-146. doi:10.1177/039463201402700120. PMID 24674691. 
  • Kelesidis T, Pothoulakis C (March 2012). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2). ss. 111-125. doi:10.1177/1756283X11428502. PMC 3296087 $2. PMID 22423260. 
  • Berni Canani R, Cucchiara S, Cuomo R, Pace F, Papale F (July 2011). "Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children". European Review for Medical and Pharmacological Sciences. 15 (7). ss. 809-822. PMID 21780551. 
  • Sulik-Tyszka B, Snarski E, Niedźwiedzka M, Augustyniak M, Myhre TN, Kacprzyk A, ve diğerleri. (June 2018). "Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients". Probiotics and Antimicrobial Proteins. 10 (2). ss. 350-355. doi:10.1007/s12602-017-9332-4. PMC 5973998 $2. PMID 28948565. 

scitechdaily.com

web.archive.org